Pathway-27 Consortium

 

PATHWAY-27 includes 25 partners broadly distributed in Europe: west to east, south to north Europe, including one Candidate Country (Turkey). The EU Consortium consists of different organisation types, namely: Universities, Research Institutes and SMEs.

Partners in Sweden

KAROLINSKA INSTITUTET (KI)


Karolinska Institutet (KI) was founded by King Karl XIII in 1810. Today, KI is one of the world´s leading medical universities and accounts for over 40 per cent of the medical academic research conducted in Sweden.
Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine. KI has a close relationship to the clinical milieu, a well established infrastructure and a competitive track record of successful international collaborations.
Previous experience related to the task: WP3 KI has developed an array of methods to mechanistically study human adipocyte function in vitro and perform advanced metabolic studies in vivo in our well-equipped clinical research unit. Large tissue banks including plasma/sera, DNA, adipose tissue (visceral/subcutaneous) and liver from lean and obese adult cohorts. Detailed clinical phenotypes available from all subjects. Specific areas of expertise related to the proposed tasks: in vitro and in vivo studies of human adipocytes, bioinformatics, systems biology, obesity, insulin resistance, metabolism, genetics, clinical trials.

Scientific responsible: Peter Arner, Professor, M.D. (Peter.Arner@ki.se)

Website: http://ki.se/

SWEDISH OAT FIBER AB / CREANUTRITION (SOF)

 

Swedish Oat Fiber is a leading supplier of oat bran with high quality beta-glucans. SOF Swedish Oat Fiber AB was founded in 1989 with a dedication to use the highest quality raw material to produce and process all natural and consistent quality oat bran ingredients. Extensive clinical studies have substantiated the health benefits of oat ß-glucans in human nutrition. As it has always been of strong interest to prove the specific functional properties of OatWell® oat bran, many studies have been conducted using this product as key ingredient. This has given extensive knowledge about the functional properties as well as provided substantial proof of the effects of ingesting OatWell® oat bran. The SOF technology is developed to produce OatWell® oat bran, rich in ß-glucan, with high molecular weight and aqueous viscosity for optimized bioactivity. The SOF plant meets the highest possible standards for large scale food production and environmental demands and is, among others, Kosher and FSSC 22000 certified. In 2002 CreaNutrition AG was founded as a fully owned subsidiary of SOF, in charge of Sales, Marketing and Regulatories.
CreaNutrition/SOF has been at the forefront of allowed health claims in Europe. Following an application from CreaNutrition/SOF submitted pursuant to Article 14 of Regulation (EC) No 1924/2006, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies concluded that a cause and effect relationship has been established between the consumption of oat beta-glucans and the lowering of blood LDL-cholesterol concentrations and published a positive opinion on a heart disease risk reduction health claim for the consumption of 3 g/day oat beta-glucans (adoption in 2012). Two additional positive opinions from the EFSA include reduction of postprandial glycemic response and gut health.
Swedish Oat Fiber is part of a large network connecting application research and production capabilities, which aims to support product development for extruded cereals, drinks, bars, bakery goods as well as food supplements. Since January 1st, 2013, the activities from CreaNutrition have been taken over by DSM Nutritional Products for an exclusive distribution agreement with SOF outside the Nordic countries.

Scientific responsible: Frédéric Prothon (f.p@sweoat.se)

Website: www.oatwell.com

Project partner(s):